AMR Benchmark homepage
More pharma companies join the leaders in 2020, yet progress on AMR is slow
The AMR Benchmark: independent report on pharma’s response to AMR
The 2020 Antimicrobial Resistance Benchmark compares how pharmaceutical companies are bringing AMR under control. It covers R&D, responsible manufacturing, appropriate access and stewardship.
Pfizer is the first company to share raw data on the spread of resistance
13 companies are running or supporting antimicrobial resistance (AMR) surveillance programmes, compared with nine in 2018. Pfizer is the first to share raw data.
Pharma companies miss opportunities to make antibiotics available
Pharmaceutical companies are not registering new antibiotics where need is greatest. Older, clinically useful antibiotics are not widely supplied.
News related to the Antimicrobial Resistance Benchmark
2020 Antimicrobial Resistance Benchmark
What leaders say
"The AMR Benchmark brings much-needed clarity to how pharmaceutical companies approach AMR, which means investors can assess how pharmaceutical companies manage opportunities and risks created by drug-resistant infections. Such scrutiny by investors will spur pharma executives to greater activity."
Former Chair of the UK Review on AMR
"This independent Antimicrobial Resistance Benchmark is a huge step forward and shines a light on the pharmaceutical industry’s progress in tackling drug-resistant infections. It can help pave the way for a transparent learning culture where best practice is shared, progress celebrated, and gaps where further work is needed are identified.”
Dame Sally Davies
Professor Dame Sally Davies, Chief Medical Officer and co-convener of the UN Inter-Agency Co-ordination Group on AMR
"We desperately need new antibiotics, but we can’t let the new ones go to waste. The AMR Benchmark is an important tool to spur progress on innovation, appropriate use, and clean manufacturing, providing an independent assessment following the Davos Declaration and the Industry Roadmap released in 2016."
Professor of Law at Boston University and Executive Director of CARB-X